3646 results for «594»
3646 results
Imaging for structural heart disease intervention
19 Feb 2023 – From PCR Tokyo Valves 2023
Consult this session if you want to learn about imaging in structural heart interventions by exploring series of slides on restoration post transcatheter mitral valve repair, diagnostic performance of CT angiography, and AI in aortic complex measurement for TAVI, and more!
Complex CTO challenges
22 Sep 2023 – From AICT-AsiaPCR 2023
Gain valuable insights into overcoming CTO challenges in this session: learn how IVUS can come to the rescue in cases of main branch cut-off, discover successful recanalization techniques for right coronary artery CTOs using very long epicardial channels and explore the best approaches for managing complex...
Complication and bailout of TAVI
18 Feb 2023 – From PCR Tokyo Valves 2023
As TAVI is never risk-free, learn about bailout techniques to counter various complications. This session explores cases such as failure to release aortic stenosis after implantation of a self-expanding valve, retrieving a pigtail catheter straightener dropped into aorta and balloon rupture during TAVI.
AsiaPCR/SingLIVE 2017: closing Ceremony and Awards
21 Jan 2017 – From AsiaPCR/SingLIVE 2017
Consult the Closing ceremony and awards session from AsiaPCR/SingLIVE 2017, where W. Wijns addresses the subject of what to expect in the field of Interventional Cardiology in 2017, and the speakers present the award winners of this year's best clinical cases namely R. Fukuhara, Japan, W....

Chairperson

Chairperson
TRILUMINATE pivotal: A landmark randomized clinical trial of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation
04 Mar 2023
Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).

Author

Author
Which AF patients may benefit from LAA closure?
02 Jul 2026
Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Author